Prognotic Role of CMR in Takotsubo Syndrome
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Cagliari
About this trial
The primary objective of this observational registry is to develop a comprehensive clinical and imaging score (incorporating echocardiography and cardiac magnetic resonance data) that enhances risk stratification for patients with Takotsubo syndrome.
The secondary objectives of this registry are as follows:
Investigate the diagnostic value of cardiac magnetic resonance parameters in predicting in-hospital and long-term outcomes in patients with Takotsubo syndrome.
Compare the proposed risk stratification score for patients with Takotsubo syndrome with previously existing scores.
Investigate the contribution of machine learning models in predicting in-hospital and long-term outcomes compared to standard clinical scores.
The design and rationale of this registry are available at 10.1097/RTI.0000000000000709
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Takotsubo syndrome diagnosis (according to Position Statement of the European Society of Cardiology Heart Failure Association)
Adult patients ( > 18y old)
Availability at baseline of clinical variables, standard transthoracic echocardiography, and cardiovascular magnetic resonance acquisition
Disqualifiers
<18 y old
Lack of transthoracic echocardiography and cardiovascular magnetic resonance examinations
Preexisting cardiomyopathies
Previous myocardial infarction
Trial population
Takotsubo syndrome patients
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
All-cause mortality
cardiovascular death, pulmonary edema, arrhythmias, heart failure, sudden car- diac death, and major adverse cardiac and cerebrovascular events (MACCE) defined as a composite endpoint of death from any cause, myocardial infarction, recurrence of Takotsubo syndrome, transient ischemic attack, and stroke.
Time frame
2 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Cagliari
Lead sponsor
Centro Cardiologico Monzino
Collaborator
IRCCS San Raffaele
Collaborator
University of Roma La Sapienza
Collaborator
Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy
Collaborator
University of Messina
Collaborator
University of Udine
Collaborator
Vannini Hospital Rome
Collaborator
A.O.U. Città della Salute e della Scienza - Molinette Hospital
Collaborator
University Hospital, Bonn
Collaborator
University Hospital, Rouen
Collaborator
Source ClinicalTrials.gov